Latest News
News Functions
Additional Functions
1 May 2020
ADC Therapeutics SA
ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield
27 April 2020
ADC Therapeutics SA
ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors
24 April 2020
ADC Therapeutics SA
ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
21 April 2020
ADC Therapeutics SA
ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer
19 March 2020
ADC Therapeutics SA
ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company
10 January 2020
ADC Therapeutics SA
ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs
9 January 2020
ADC Therapeutics SA
ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
9 December 2019
ADC Therapeutics SA
ADC Therapeutics Announces Oral Presentation of Interim Efficacy Data from Pivotal Phase 2 Clinical Trial of ADCT-402 (Loncastuximab Tesirine) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma at 61st ASH Annual Meeting
6 November 2019
ADC Therapeutics SA
ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting
5 November 2019
ADC Therapeutics SA
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer
4 November 2019
ADC Therapeutics SA
ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research
17 October 2019
ADC Therapeutics SA
ADC Therapeutics Doses First Patients in Pivotal Phase 2 Clinical Trial of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma
6 September 2019
ADC Therapeutics SA
ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering
26 August 2019
ADC Therapeutics SA
ADC Therapeutics and Freenome Enter Biomarker Development Collaboration
6 August 2019
ADC Therapeutics SA
ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial
9 July 2019
ADC Therapeutics SA
ADC Therapeutics Announces Final Close of Series E Financing Expansion
21 June 2019
ADC Therapeutics SA
ADC Therapeutics Presents Clinical Data on ADCT-402 and ADCT-301 in Subtypes of Relapsed or Refractory Lymphoma at the 15th International Conference on Malignant Lymphoma
12 June 2019
ADC Therapeutics SA
ADC Therapeutics Announces Completion of a Series E Financing Expansion
ADC Therapeutics SA
ADC Therapeutics Announces Presentations at the 15th International Conference on Malignant Lymphoma
24 April 2019
ADC Therapeutics SA
ADC Therapeutics and Adagene Announce License Agreement
20 February 2019
ADC Therapeutics SA
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and Ibrutinib in Patients with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
13 February 2019
ADC Therapeutics SA
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI(R) (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
16 January 2019
ADC Therapeutics SA
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
4 January 2019
ADC Therapeutics SA
ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors
3 January 2019
ADC Therapeutics SA
ADC Therapeutics to Appoint Peter Hug, Ph.D., to Board of Directors
5 December 2018
ADC Therapeutics SA
ADC Therapeutics Presents Updated Data from Clinical Trials of Novel Antibody Drug Conjugates
27 November 2018
ADC Therapeutics SA
ADC Therapeutics Announces First Patients Dosed in Phase I/II Clinical Trial of ADCT-602 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
14 November 2018
ADC Therapeutics SA
ADC Therapeutics Announces Presentations at 60th American Society of Hematology (ASH) Annual Meeting
8 November 2018
ADC Therapeutics SA
ADC Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
7 August 2018
ADC Therapeutics SA
ADC Therapeutics Doses First Patient in Pivotal Clinical Trial of ADCT-402 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma